Related Experiment Video
Updated: Feb 13, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
New and emerging therapies in treatment of Clostridium difficile infection
Hemant Goyal1, Abhilash Perisetti2, M Rubayat Rehman2
1Department of Internal Medicine, Mercer University School of Medicine.
Abstract:
Clostridium difficile infection (CDI) represents one of the most serious nosocomial infections that have grown dramatically over the past decade. Vancomycin and metronidazole are currently used as a standard therapy for CDI. Metronidazole is recommended as a first-line therapy for mild-to-moderate infections and vancomycin is mainly used for severe and/or refractory cases. However, studies have demonstrated that there are quite high CDI relapse rates with both of these medications, which represents a challenge for clinicians. Over the last decade, a number of newer and novel therapeutic options have emerged as promising alternatives to these standard CDI therapies. The following review provides the updated summaries of these newer therapeutic agents and their status in the treatment of CDI.
Insights
Clostridium difficile infection (CDI) treatment faces challenges with high relapse rates from standard therapies like vancomycin and metronidazole. This review summarizes promising newer therapeutic options for managing recurrent CDI.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Clostridium difficile infection (CDI) is a significant nosocomial pathogen with increasing incidence.
- Current standard therapies, vancomycin and metronidazole, are associated with high CDI relapse rates.
- Managing recurrent CDI remains a clinical challenge.
Purpose of the Study:
- To review and summarize novel therapeutic agents for Clostridium difficile infection.
- To provide an update on the status of emerging treatments for CDI.
- To highlight promising alternatives to current standard therapies.
Main Methods:
- Literature review of recent studies on CDI therapeutics.
- Analysis of clinical trial data for newer agents.
- Synthesis of information on emerging treatment options for CDI.
Main Results:
- Several novel therapeutic agents show promise in treating CDI.
- Emerging therapies aim to reduce high relapse rates associated with standard treatments.
- The review details the current status and efficacy of these new options.
Conclusions:
- Newer therapeutic options offer potential improvements in managing Clostridium difficile infection.
- These agents may help overcome the challenge of high CDI recurrence.
- Further research and clinical application of novel therapies are warranted.
More Related Videos
Related Concept Videos
Emerging Adulthood
Gene Therapy
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response
Group Therapy

